• The document contains the transcript of Aarti Drugs Limited's Q1 FY27 Earnings Conference Call held on August 03, 2026.
  • The conference call was moderated and included participation from management representatives: Mr. Adhish Patil (COO and CFO), Mr. Harshit Savla (Joint Managing Director), Mr. Harit Shah (Whole-Time Director), and Mr. Vishwa Savla (Managing Director of Pinnacle Life Science Private Limited).
  • The purpose of the call was to discuss the company's quarterly performance for the period ended June 30, 2026, with reference to financial results and investor presentation already uploaded to stock exchanges and the company website.
  • The company indicated that no unpublished price sensitive information (UPSI) would be shared, as stated in the disclaimer: "this conference call contains forward-looking statements about the company which are based on the beliefs, opinions, and expectations of the company as on date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict."

Financial Highlights Discussed

  • Consolidated Q1 FY27 Performance: Revenue stood at INR703.6 crores (19% YoY growth from INR590.8 crores), EBITDA at INR96.9 crores (30% YoY growth from INR74.4 crores), EBITDA margin at 13.8% (120 bps expansion), PBT at INR69.2 crores (35% YoY growth from INR51.1 crores), PBT margin at 9.9% (120 bps expansion), PAT at INR50.1 crores (compared to INR54.0 crores in Q1 FY26 which included a principal tax refund of INR15 crores; excluding this, growth would be 29% YoY).
  • Stand-alone Business: Revenue stood at INR627.6 crores (20% YoY growth from INR521.3 crores), contributing 89% to consolidated revenue. Domestic revenue grew 25% YoY while export revenue grew 12% YoY.
  • API Business Breakdown: Antibiotic therapeutic category contributed 35.0%, antiprotozoal 18.5%, anti-inflammatory 11.9%, antidiabetic 18.2%, antifungal 10.2%, and others 6.1%.
  • Formulations Segment: Revenue stood at INR81.6 crores (8% YoY growth from INR75.8 crores), with exports contributing 74%.

Operational and Strategic Updates

  • Sayakha Facility: Operated at nearly 65% utilization in Q1 FY27, strengthening backward integration capabilities especially for antidiabetic segment. Methylamine plant reached 64-65% utilization (roughly 60 tons per day, ~3,500 tons for the quarter).
  • Capacity Expansion Plans: Metformin capacity scaling from 1,400 tons/month to ~2,200 tons/month, including 500-550 tons/month USFDA-approved capacity (expected in 10-12 months). USFDA plant expansion planned with 3 additional production lines (~10 tons/month each).
  • Baddi Formulations Facility: Brownfield expansion progressing to nearly double oral solid dosage manufacturing capacity.
  • Tarapur Salicylic Acid Facility: Produced only 67 tons in Q1 due to equipment installation for derivatives production. Methyl salicylate derivative capacity of 350-400 tons/month commissioned with trial batches started. Anti-dumping duty expected in approximately one year.
  • Regulatory Approvals: Facilities hold approvals from USFDA, UK agencies, EDQM. European CEP approvals for 9 products. US DMF already filed for Metformin.

Market and Demand Commentary

  • Pricing Environment: API prices witnessed upward movement industry-wide due to geopolitical tensions (West Asia conflict) affecting supply chains. Metformin prices increased ~20% compared to pre-war levels, though slightly lower than March-April peaks.
  • Volume vs Price Growth: Q1 saw ~3.5% aggregate volume growth with ~16-17% price growth. Domestic demand affected by high prices while export demand remained stable.
  • Margin Outlook: Targeting 14-15% EBITDA margins through improved utilization (Sayakha expected to contribute ~1% to gross margins at peak) and operational efficiencies.
  • Growth Guidance: Expecting 10-15% volume growth over next two years driven by capacity expansions and market share gains, particularly in regulated markets.

Additional Notes

  • The document is a regulatory filing containing the complete transcript of the earnings conference call submitted to BSE and NSE.
  • The transcript includes full Q&A session with analysts from Vaikarya Fund, Trinetra Asset Managers, Dolat Capital, Turtle Capital, and Antifragile Thinking.
  • No financial data beyond what was disclosed in the earnings presentation and discussed during the call was included in this announcement.
  • The company clarified that the transcript may contain factual errors and in case of discrepancy, the audio recordings uploaded on stock exchanges on August 3, 2026 would prevail.